![]() ![]() Henriksen G, Breistøl K, Bruland ØS, Fodstad Ø, Larsen RH. High-linear energy transfer irradiation targeted to skeletal metastases by the alpha-emitter 223Ra: adjuvant or alternative to conventional modalities? Clin Cancer Res. Alpha emitter radium-223 and survival in metastatic prostate cancer. Parker C, Nilsson S, Heinrich D, Helle SI, O’Sullivan JM, Fosså SD, et al. Our results support the use of Ra-223 earlier in the treatment pathway.Ĭopyright © 2020 Wolters Kluwer Health, Inc. We found a significant survival benefit when Ra-223 was used earlier in the mCRPC treatment pathway, with additional survival advantage seen in those patients completing all six Ra-223 cycles. There was no difference in the number of patients completing the recommenced six cycles of therapy between the groups. Median survival in group 1 was incrementally significantly improved, compared to group 2 within these patients (665 days vs. Subgroup analysis of 111/191 (58%) patients that completed the recommended six Ra-223 therapy cycles showed additional improved survival. Median survival in group 1 was significantly improved, compared to group 2 (448 days vs. One hundred twenty-one (63%) received one prior therapy (group 1) and 70 (37%) received two prior therapies (group 2). One hundred ninety-one mCRPC patients received Ra-223 therapy during the study period. Overall survival, number of prior lines of therapy commenced before Ra-223 initiation and number of Ra-223 therapy cycles completed were identified. Retrospective analysis of all mCRPC patients receiving Ra-223 therapy at a single UK centre over a 70-month period. We evaluated how this change affects overall survival and the optimal timing of Ra-223 in the mCRPC treatment pathway. Recent guidance change recommends Ra-223 following at least two prior therapies for mCRPC. Radium-223 dichloride (Ra-223) therapy improves overall survival in bony metastatic castration-resistant prostate cancer (mCRPC) patients.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |